Some of the members of Brazil's most corrupt wealthy elites were major contributors to the rip-off culture that saw a spike in public procurement road construction contract profiteering during the Mahama administration's years in power.
Perhaps we can change the nature of our relationship with Brazil - now that many of Brazil's wealthiest and most powerful individuals in that nation's intertwined worlds of politics and business have been tried and punished for corruption during the post-Lula period in which Brazil undertook reforms as an anti-corruption wave swept across South America's biggest nation - under President Akufo-Addo to a win-win one based on transparency.
In that regard, Ghana's minister of health, Hon Kweku Agyemang Manu, ought to liaise with his Brazilian counterpart, to replicate a successful free H.I.V. drug programme that is reducing the numbers of new H.I.V. infections amongst Brazil's most vulnerable young people, in Ghana.
We must encourage Ghanaian pharmaceutical manufacturers to collaborate with their Brazilian counterparts to produce generic drugs for such an
initiative in Ghana - which could be paid for simply by closing the loophole that shipping companies are allegedly exploiting to levy charges they don't apparently demand from their clients anywhere else in the world but in Ghana, fior example. Ditto preventing the smuggling of gold from our
shores - and censuring that all exporters pay taxes due the Ghanaian nation-state.
(Incidentally, as news reports filter through from South East Asia about the emergence of a new drug-resistant super-malaria, Hon. Kweku Agyeman Manu should alert those in charge of public health in our country, to be on the lookout, as it could be brought here by container ships and aeroplanes from that region.)
Finally, to serve as an inspiration to members of our nation's political class, particularly those from the younger generation, such as Hon. Zenator Rawlings, we are posting a culled New York Times article by Shasta Darlington, entitled: " Brazil Fights H.I.V. Spike in Youths With Free Preventive Drug".
Please read on:
"Americas
Brazil Fights H.I.V. Spike in Youths With Free Preventive Drug
Leer en español
By SHASTA DARLINGTON DEC. 12, 2017
Continue reading the main story
Share This Page
Share
Tweet
Email
More
Save
Photo
Piero Mori, right, and a friend both make use of the PrEP program, short for pre-exposure prophylaxis. “Condoms will always be the most complete protection,” Mr. Mori said. “But for those who just can’t or won’t use them, PrEP is a salvation. It protects you against the most serious disease.” Credit Dado Galdieri for The New York Times
SÃO PAULO, Brazil — Seeking to stem a sharp rise in H.I.V. cases among young people, Brazil began offering a drug this month that can prevent infection to those deemed at high risk.
Brazil is the first country in Latin America, and among the first in the developing world, to adopt the pill Truvada, under a program known as PrEP, short for pre-exposure prophylaxis, as an integral part of its preventive health care policy.
The blue pill — which drastically reduces the risk of contracting the virus when taken daily — will be made available at no cost to eligible Brazilians at 35 public health clinics in 22 cities during an inaugural phase of the program.
The Brazilian Health Ministry is paying Gilead Sciences, the American manufacturer of the drug, about 75 cents a dose, a fraction of the price users pay in the United States, where the pill sells for upward of $1,600 for a month’s supply.
The drug is being rolled out at a crucial time in Brazil, with the country’s health officials particularly alarmed by the rise of the virus among young men and other groups considered at higher risk.
Continue reading the main story
Advertisement
Continue reading the main story
Between 2006 and 2015, the number of AIDS cases in men aged 15-19 almost tripled, to 6.9 cases per 100,000 people. Among men 20-24, the rate almost doubled to 33.1 cases per 100,000, according to U.N.AIDS, a United Nations agency that coordinates H.I.V. prevention policy around the world.
Approximately 48,000 new cases of H.I.V. were reported in Brazil in 2016 and about 14,000 deaths related to AIDS, the agency said.
While the transmission of the virus from mother to child has been significantly reduced, about one in 10 men who have sex with men in Brazil have H.I.V., the agency said.
“Our hope is that with PrEP and other measures we can reduce the rate of new infections,” said Adele Benzaken, the director of the AIDS department at Brazil’s Health Ministry. “But it’s a big challenge.”
PrEP is being made available to prostitutes, transgender people, men who have sex with men, some drug users and people in relationships with partners who have H.I.V.
Brazil has long been recognized for its strong response to the H.I.V. epidemic. It challenged pharmaceutical companies in the 1990s by producing generic versions of costly antiretroviral drugs, which lowered prices globally. Brazil’s government buys and distributes more condoms than any other country, and in 2013 it started providing antiretroviral therapy free to all H.I.V.-positive adults seeking care.
Proponents of PrEP say Brazil’s experience will show the economic benefits of investing in prevention.
Advertisement
Continue reading the main story
“With the addition of PrEP, Brazil is using all of the strategies that we recommend,” said Georgiana Braga-Orillard, the director of U.N.AIDS Brazil. “This is a large-scale operation, and Brazil could become an example to all of Latin America that we need to see an integrated approach.”
Since the United States Federal Drug Administration approved Truvada as a prevention drug for H.I.V. in 2012, several countries have sought to make it available and affordable to people at risk of contracting H.I.V.
Photo
Bottles of Truvada, the branded PrEP drug manufactured by Gilead. Credit Dado Galdieri for The New York Times
For the first year of Brazil’s program, the Health Ministry spent $2.7 million for 3.6 million pills. Screening and additional care will be provided at no cost at public clinics.
Ms. Benzaken, the ministry official, said Brazil expected to spend less on this preventive care next year as generic versions of the drug arrive in the market.
“It was a good deal,” she said. “But we need to bring the price down even more.”
She said two pharmaceutical companies, including Mylan, had applied to Brazil’s health regulatory agency, Anvisa, for approval of generic versions of Truvada.
Newsletter Sign Up
Continue reading the main story
The Interpreter Newsletter
Understand the world with sharp insight and commentary on the major news stories of the week.
You agree to receive occasional updates and special offers for The New York Times's products and services.
See Sample Privacy Policy Opt out or contact us anytime
People have grown less concerned about H.I.V., leading to a decline in the use of condoms, said Jose Valdez Madruga of the São Paulo Health Secretariat, who was one of the coordinators of a PrEP trial in Brazil carried out ahead of its implementation. The drug provides an additional safeguard.
“With PrEP, it puts the decision in the hands of one person, said Mr. Madruga, the head of the secretariat’s AIDS and sexually transmitted disease center. “You don’t need the agreement of the other partner, as with condoms.”
According to a survey in Brazil by the gay-dating app Hornet and U.N.AIDS, 36 percent of respondents said they would probably use PrEP if it were available.
Critics of PrEP have said it incentivizes condomless sex, leading to the spread of other sexually transmitted diseases.
Advertisement
Continue reading the main story
Marcio Pierezan, 29, a patient who participated in the trial, said those fears were overblown. He started taking the pill two years ago.
“It was at a time when four close friends had tested positive for H.I.V., and I was in an open relationship with someone who had tested positive,” he said. “I was in constant fear that I would be next, even though I used condoms.”
Mr. Pierezan says that the pill is as an added protection, but that he never stopped using condoms. “It became part of my routine,” he said. “I take it with coffee in the morning, and it’s been a huge relief for me, my friends, my mother!”
Piero Mori, 34, a systems analyst who is gay, says he never liked using condoms, which meant new sexual encounters often brought weeks of anxiety as he tested yet again for H.I.V.
“Condoms will always be the most complete protection,” he said. “But for those who just can’t or won’t use them, PrEP is a salvation. It protects you against the most serious disease.”
The new tool in Brazil’s effort to contain the spread of H.I.V. is being deployed as budget shortfalls in some states have led to personnel and medicine shortages that have crippled several hospitals. Additionally, public schools that provide comprehensive sex education have come under attack from conservative politicians.
Still, health officials have high hopes for the impact PrEP can have on keeping people healthy. In order to promote it, they are considering partnering with popular YouTube personalities and advertising on online dating apps.
“We don’t have all the answers yet,” Ms. Benzaken said. “But we are using all the tools at our disposal.”
Correction: December 12, 2017
An earlier version of this article misidentified the H.I.V. prevention pill to be given away in Brazil. The drug is Truvada, not PrEP, which describes the overall treatment strategy, pre-exposure prophylaxis.
Continue reading the main story
Trending
Alabama Senate Race Between Roy Moore and Doug Jones Carries National Implications
Ken Friedman, Power Restaurateur, Is Accused of Sexual Harassment
Hacking the Tax Plan: 13 Ways to Profit Off the Republican Tax Bill
‘Star Wars: The Last Jedi’ Embraces the Magic and Mystery. Read Our Review.
Republicans, Closing In on Final Tax Bill, Aim for a Vote Next Week
Another Human Foot Washes Ashore in Canada. That Makes 13.
At an Alabama Rally, a Father’s Grief Over His Gay Daughter
Trump Says Gillibrand ‘Would Do Anything’ for Campaign Donations
Charles Jenkins, 77, U.S. Soldier Who Regretted Fleeing to North Korea, Dies
Op-Ed Columnist: What Happens if the Tax Bill Is a Revenue Disaster?
View More Trending Stories »
What's Next
Loading...
Go to Home Page »
Site Index The New York Times
Site Index Navigation
News
World
U.S.
Politics
N.Y.
Business
Tech
Science
Health
Sports
Education
Obituaries
Today's Paper
Corrections
Opinion
Today's Opinion
Op-Ed Columnists
Editorials
Op-Ed Contributors
Letters
Sunday Review
Video: Opinion
Arts
Today's Arts
Art & Design
Books
Dance
Movies
Music
N.Y.C. Events Guide
Television
Theater
Video: Arts
Living
Automobiles
Crossword
Food
Education
Fashion & Style
Health
Jobs
Magazine
N.Y.C. Events Guide
Real Estate
T Magazine
Travel
Weddings & Celebrations
Listings & More
Reader Center
Classifieds
Tools & Services
N.Y.C. Events Guide
Multimedia
Photography
Video
NYT Store
Times Journeys
Subscribe
Manage My Account
NYTCo
Subscribe Home Delivery Digital Subscriptions Crossword
Email Newsletters Alerts Gift Subscriptions Group Subscriptions Education Rate
Mobile Applications Replica Edition
Site Information Navigation
© 2017 The New York Times Company
Home
Search
Accessibility concerns? Email us at accessibility@nytimes.com. We would love to hear from you.
Contact Us
Work With Us
Advertise
Your Ad Choices
Privacy
Terms of Service
Terms of Sale
Site Information Navigation
Site Map
Help
Site Feedback
Subscriptions
Get The New York Times for just $1.88 a week. SUBSCRIBE NOW
Log in
Subscribe to debate, not division.
Get The New York Times for just $1.88 a week.
Enjoy everything The New York Times has to offer.
Already a subscriber? Login"
End of culled New York Times webpage containing culled article by Shasta Darlington.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment